A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, dry eye, retinal diseases and other diseases of the eye
News Highlights
Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s... Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated ... Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial R...STOCK Quote
NASDAQ: AERI
$13.97USD
Jul 2, 4:00 PM ET
VOLUME
0
DAY LOW/HIGH
$13.81/$14.97
52 - WEEK LOW/HIGH
$10.80/$26.68
